RxDoctor Payments Data

Gowrappala Ramesh, MD

Gastroenterology · Houston, TXNPI 1053377051

Payments from drug & device makers

$159,156in general payments, 2019–2025

Across 827 payments — averaging $192.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$56K
  • E.r. Squibb & Sons, L.L.C.$40K
  • Bausch Health US, LLC$20K
  • AbbVie$13K
  • Amgen$11K
  • Pfizer$5K
  • plus $14K from 35 others

What the payments were for

  • Consulting fees$1,6652%
  • Speaking & faculty fees$58,30370%
  • Travel & lodging$6,2037%
  • Food & beverage$17,12221%
  • Education$1910%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$159,156 in reported general payments places this provider in the 90th percentile of 1,350 gastroenterology providers in Texas.

See all gastroenterology providers in Texas

Medicare billing

Part B allowed, 2024
$105,057
Medicare patients
429
Services billed
836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntyvioVedolizumab13$98,572
CreonLipase/Protease/Amylase15$56,238
LinzessLinaclotide44$50,949
TrulancePlecanatide44$34,407
VoqueznaVonoprazan Fumarate22$27,155
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates289$17,473
Mesalamine20$9,480
Dexlansoprazole DrDexlansoprazole21$9,133
CholestyramineCholestyramine (With Sugar)33$4,361
Omeprazole306$4,213
Esomeprazole Magnesium70$2,702
Pantoprazole Sodium155$2,229
Famotidine125$1,613
Ondansetron OdtOndansetron33$1,080
Dicyclomine Hcl19$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$12,918$107,18759 claims
Takeda Pharmaceuticals U.S.A., Inc.Entyvio$2,961$98,57213 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,124$34,40744 claims
Phathom Pharmaceuticals, Inc.Voquezna$55,569$27,15522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,350 gastroenterology providers in Texas.

Other gastroenterology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →